ITC Limited — Board Meeting, 01-08-2025: Outcome of Board Meeting

ITC's Board has approved consolidated financial results for the quarter ended June 30, 2025. Continuing operations delivered a revenue of ₹23,129.35 Cr and a profit of ₹5,343.41 Cr. Strategic moves include the acquisition of Sresta Natural Bioproducts (SNBPL), now a wholly-owned subsidiary, with its results impacting comparability. The Board also greenlighted SNBPL's and Wimco Limited's amalgamation with ITC. Additionally, the company increased its stake in Mother Sparsh Baby Care to 39.47% and issued new shares under its ESOP scheme, growing its paid-up capital.